Xencor to Host First Quarter 2023 Financial Results Webcast

Xencor, Inc. , a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will release first... | May 1, 2023

Related Keywords

Xencor Xmab , Xencor Inc , Nasdaq , , Xencor , Nc Stock Exchange , News , Information , Press Release , Iopharmaceutical , Company , Developing , Engineered , Antibodies , End , Ytokines , Or , The , Treatment , F , Dancer , Autoimmune , Oday , Nnounced , It , Hill , Elease Xncr Us98401f1057 ,